AstraZeneca: FDA approves Lynparza as first-line treatment
(CercleFinance.com) - AstraZeneca said on Thursday that the US Food and Drug Administration has approved its cancer cell killer Lynparza for use in BRCA-mutated advanced ovarian cancer.
The drugmaker and its US partner Merck said the FDA has approved Lynparza for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line chemotherapy.
AstraZeneca and Merck took the opportunity to unveil positive results from a Phase III trial on Lynparza tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment.
According to the drugmakers, Lynparza significantly improved objective response rate compared to chemotherapy in platinum-sensitive relapsed patients who had two or more prior lines of chemotherapy.
AstraZeneca also said that two Phase III trials for another of its drugs, roxadustat, each met their primary endpoints for the treatment of patients with anaemia in chronic kidney disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The drugmaker and its US partner Merck said the FDA has approved Lynparza for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube or primary peritoneal cancer who are in complete or partial response to first-line chemotherapy.
AstraZeneca and Merck took the opportunity to unveil positive results from a Phase III trial on Lynparza tablets in 266 patients with relapsed ovarian cancer after two or more lines of treatment.
According to the drugmakers, Lynparza significantly improved objective response rate compared to chemotherapy in platinum-sensitive relapsed patients who had two or more prior lines of chemotherapy.
AstraZeneca also said that two Phase III trials for another of its drugs, roxadustat, each met their primary endpoints for the treatment of patients with anaemia in chronic kidney disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.